Inventor · disambiguated record
Juliane Walz
Also filed as: WALZ JULIANE · WALZ JULIANE SARAH
25 granted patents·15 pending applications·6 citations·filing 2018–2025
93Inventor score
Top patents by PatentIndex Score
40 records- 0192US10364271B2Immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (CLL)IMMATICS BIOTECHNOLOGIES GMBH·Filed 2018·Granted Jul 30, 2019·2 cites·23 claims
- 0290US11542303B2Peptides and combination thereof for use in the immunotherapy against cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Jan 3, 2023·1 cites·9 claims
- 0389US10450346B2Immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (CLL)IMMATICS BIOTECHNOLOGIES GMBH·Filed 2019·Granted Oct 22, 2019·1 cites·20 claims
- 0485US10906938B2Cell epitopes and combination of cell epitopes for use in the immunotherapy of myeloma and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted Feb 2, 2021·1 cites·28 claims
- 0583US11135246B2Peptides and combination of peptides for use in immunotherapy against leukemias and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted Oct 5, 2021·1 cites·22 claims
- 0679US11560405B2Peptides and combination thereof for use in the immunotherapy against cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2022·Granted Jan 24, 2023·0 cites·20 claims
- 0779US10570175B2Immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (CLL)IMMATICS BIOTECHNOLOGIES GMBH·Filed 2019·Granted Feb 25, 2020·0 cites·20 claims
- 0878US10668137B2Immunotherapy against several tumors of the blood, such as acute myeloid leukemia (AML)IMMATICS BIOTECHNOLOGIES GMBH·Filed 2019·Granted Jun 2, 2020·0 cites·20 claims
- 0977US10875892B2Immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (CLL)IMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted Dec 29, 2020·0 cites·20 claims
- 1076US10730910B2Immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (CLL)IMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted Aug 4, 2020·0 cites·20 claims
- 1175US11559550B2Peptides and combination of peptides for use in immunotherapy against leukemias and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2022·Granted Jan 24, 2023·0 cites·20 claims
- 1275US10925949B2Immunotherapy against several tumors of the blood, such as acute myeloid leukemia (AML)IMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted Feb 23, 2021·0 cites·20 claims
- 1375US10898562B1Immunotherapy against several tumors of the blood, such as acute myeloid leukemia (AML)IMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted Jan 26, 2021·0 cites·20 claims
- 1475US10525115B2Immunotherapy against several tumors of the blood, such as acute myeloid leukemia (AML)IMMATICS BIOTECHNOLOGIES GMBH·Filed 2019·Granted Jan 7, 2020·0 cites·20 claims
- 1575US2023346837A1Peptides and combination thereof for use in the immunotherapy against cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Application pending·0 cites
- 1674US11103534B2Peptides and combination thereof for use in the immunotherapy against cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted Aug 31, 2021·0 cites·20 claims
- 1774US2021213065A1Peptides and combination thereof for use in the immunotherapy against cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Application pending·0 cites
- 1874US2021107941A1Novel cell epitopes and combination of cell epitopes for use in the immunotherapy of myeloma and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Application pending·0 cites
- 1974US2022332760A1Peptides and combination thereof for use in the immunotherapy against cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2022·Application pending·0 cites
- 2073US11427614B2Peptides and combination thereof for use in the immunotherapy against cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2018·Granted Aug 30, 2022·0 cites·16 claims
- 2173US10919933B2Cell epitopes and combination of cell epitopes for use in the immunotherapy of myeloma and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted Feb 16, 2021·0 cites·28 claims
- 2273US10899794B2Cell epitopes and combination of cell epitopes for use in the immunotherapy of myeloma and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted Jan 26, 2021·0 cites·28 claims
- 2373US10813985B2Immunotherapy against several tumors of the blood, such as acute myeloid leukemia (aml)IMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted Oct 27, 2020·0 cites·20 claims
- 2473US10799571B2Immunotherapy against several tumors of the blood, such as acute myeloid leukemia (AML)IMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted Oct 13, 2020·0 cites·20 claims
- 2573US10781233B2Cell epitopes and combination of cell epitopes for use in the immunotherapy of myeloma and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2019·Granted Sep 22, 2020·0 cites·27 claims
- 2672US11020432B2Peptides and combination thereof for use in the immunotherapy against cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted Jun 1, 2021·0 cites·20 claims
- 2772US11007223B2Peptides and combination thereof for use in the immunotherapy against cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted May 18, 2021·0 cites·20 claims
- 2872US2020339656A1Peptides and combination thereof for use in the immunotherapy against cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Application pending·0 cites
- 2971US10899819B2Peptides and combination of peptides for use in immunotherapy against leukemias and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2018·Granted Jan 26, 2021·0 cites·16 claims
- 3071US2021161962A1Peptides and combination of peptides for use in immunotherapy against leukemias and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Application pending·0 cites
- 3171US2020190160A1Peptides and combination thereof for use in the immunotherapy against cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Application pending·0 cites
- 3270US10993963B2Peptides and combination of peptides for use in immunotherapy against leukemias and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted May 4, 2021·0 cites·20 claims
- 3368US2022118016A1Peptides and combination of peptides for use in immunotherapy against leukemias and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Application pending·0 cites
- 3468US2020207831A1Peptides and combination of peptides for use in immunotherapy against leukemias and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Application pending·0 cites
- 3567US2024327465A1Peptides and antigen binding proteins for use in immunotherapy against fibrolamellar hepatocellular carcinoma (fl-hcc) and other cancersUNIV TUEBINGEN MEDIZINISCHE FAKULTAET·Filed 2024·Application pending·0 cites
- 3665US2025339503A1Peptides and combinations of peptides for use in immunotherapy against acute myeloid leukemia (aml) and other hematological neoplasmsUNIV TUEBINGEN MEDIZINISCHE FAKULTAET·Filed 2025·Application pending·0 cites
- 3763US2023322865A1Peptides and Combinations of Peptides for Use in Immunotherapy Against an Infection by Sars-COV-2 (COVID-19)UNIV TUEBINGEN MEDIZINISCHE FAKULTAET·Filed 2023·Application pending·0 cites
- 3862US2023279073A1Peptides and combinations of peptides for use in immunotherapy against hematologic neoplasms and other cancersUNIV TUEBINGEN MEDIZINISCHE FAKULTAET·Filed 2022·Application pending·0 cites
- 3962US2023405108A1Peptides and combinations of peptides for use in immunotherapy against an infection by sars-cov-2 (covid-19)UNIV TUEBINGEN MEDIZINISCHE FAKULTAET·Filed 2022·Application pending·0 cites
- 4059US2025208136A1Peptides and combinations of peptides for use in immunotherapy against oropharyngeal squamous cell carcinoma (OPSCC) and other cancersUNIV TUEBINGEN MEDIZINISCHE FAKULTAET·Filed 2025·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →